Opipramol

Drug Profile

Opipramol

Alternative Names: Ensidon; G 33040; Insidon; Nisidana

Latest Information Update: 05 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis; Sun Pharmaceutical Industries
  • Class Dibenzazepines; Small molecules; Tricyclic antidepressants
  • Mechanism of Action Dopamine D2 receptor antagonists; Histamine H1 receptor antagonists; Opioid receptor agonists; Serotonin 2 receptor antagonists; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • No development reported Generalised anxiety disorder; Somatoform disorders

Most Recent Events

  • 13 Jan 2004 No development reported - Clinical-Phase-Unknown for Somatoform disorders in Germany (PO)
  • 26 Mar 2001 A study has been added to the Anxiety Disorders therapeutic trials section
  • 30 Nov 2000 Profile reviewed but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top